Table 2 Clinical and molecular parameters of breast cancers. Clinical and molecular parameters are given for each breast cancer used in this study. Module scores for each tumor were calculated from the results based on intact RNA (FF material) and based on RNA isolated from FFPE material according to our own method. N.A., data not available.
From: Expression profiling with RNA from formalin-fixed, paraffin-embedded material
Clinical classification | Immunohistochemistry | Module Score (FF/FFPE) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Tu# | T | N | Grade | ER | PR | ErbB2 | ER | HER2 | Prolif. | Histological type |
2 | 2 | 0 | 3 | 70% pos. | neg. | 1+ | 16.6/17.1 | 15.8/16.3 | 14.2/14.5 | invasive ductal |
3 | 2 | 1a | 2 | 70% pos. | pos. | 1+ | 17.2/17.7 | 16.4/16.6 | 14.3/14.0 | mixed (duct./lob) |
6 | 1c | 3a | 3 | >90% pos. | pos. | 3+ | 15.7/16.2 | 17.2/18.1 | 14.5/15.4 | invasive ductal |
8 | 2 | 2a | 3 | >90% pos. | pos. | 2+ | 16.5/17.2 | 15.8/16.3 | 14.7/14.7 | invasive ductal |
10 | 1c | N.A. | 2 | >90% pos. | pos. | 2+ | 14.5/16.6 | 15.2/16.2 | 13.5/14.4 | invasive ductal |
13 | 2 | 3a | 3 | >90% pos. | neg. | 1+ | 16.6/17.0 | 15.7/15.6 | 14.6/14.5 | invasive ductal |
14 | 1c | N.A. | 2 | >90% pos. | neg. | 1+ | 16.5/16.9 | 16.2/16.4 | 13.8/13.5 | invasive ductal |
15 | N.A. | 3 | neg. | neg. | 0 | 11.8/13.0 | 14.9/15.5 | 14.9/15.5 | invasive ductal | |
16 | 2 | N.A. | 1 | 65% pos. | pos. | 0 | 17.9/18.3 | 16.4/16.6 | 13.8/14.1 | invasive ductal/cribriform |
17 | 2 | 0 | 3 | >90% pos. | pos. | 2+ | 16.5/17.2 | 16.3/16.9 | 14.9/15.6 | invasive ductal |
18 | 2 | N.A. | 3 | neg. | neg. | 0 | 13.0/12.9 | 15.1/15.9 | 15.2/16.0 | invasive ductal |
19 | 2 | N.A. | 2 | >90% pos. | pos. | 0 | 17.2/17.6 | 15.9/16.0 | 13.8/14.2 | invasive ductal |
20 | 1c | N.A. | 2 | neg. | neg. | 0 | 12.4/13.0 | 15.7/15.9 | 14.6/15.2 | invasive ductal |
22 | 2 | 0 | 2 | N.A. | N.A. | N.A. | 16.8/17.4 | 15.6/16.1 | 13.3/13.9 | invasive ductal |